阿帕替尼联合SOX方案治疗晚期胃癌患者的疗效、不良反应及预后的影响因素分析  

Efficacy adverse reactions and the effective factors of prognos of apatinib combined with SOX in the treatment of advanced gastric cancer patients

作　　者：陈翠晓 付宝红[1] 曹丽艳[1] 董丽[1] CHEN Cui-xiao;FU Bao-hong;CAO Li-yan(Department of Oncology,Qinhuangdao First Hospital,Qinhuangdao Hebei 066000,China)

机构地区：[1]秦皇岛市第一医院肿瘤科,河北秦皇岛066000

出　　处：《临床和实验医学杂志》2025年第3期241-245,共5页Journal of Clinical and Experimental Medicine

基　　金：河北省医学科学研究课题计划(编号:20221617)。

摘　　要：目的探讨阿帕替尼联合SOX方案治疗晚期胃癌患者的疗效、不良反应及预后的影响因素。方法前瞻性选取2022年1月至2023年1月秦皇岛市第一医院收治的100例晚期胃癌患者作为研究对象,按照随机数字表法将其分为对照组(n=50)和观察组(n=50)。对照组采取SOX方案治疗,观察组在对照组基础上采用阿帕替尼治疗。3周为1个治疗周期,两组患者均治疗2个周期。比较两组患者治疗后的疗效、不良反应发生情况、生存情况。收集患者的基础资料,包括年龄、性别、美国东部肿瘤协作组(ECOG)体力状况评分、病理类型、化疗周期、TNM分期、肿瘤大小以及转移情况和甲胎蛋白水平,并分析观察组患者生存预后的影响因素。结果观察组的治疗总有效率为48.00%,显著高于对照组(20.00%),差异有统计学意义(P<0.05)。观察组与对照组的总不良反应发生率比较,差异无统计学意义(P>0.05)。观察组患者的总生存时间的平均值和中位数分别为(10.13±0.63)、(12.03±4.07)个月,均高于对照组[(7.15±0.50)、(8.01±0.41)个月],观察组患者的无疾病进展生存时间的平均值和中位数分别为(10.89±0.45)、(12.12±0.31)个月,均高于对照组[(8.23±0.42)、(8.45±0.46)个月],差异均有统计学意义(P<0.05)。不同ECOG体力状况评分、化疗周期、TNM分期、肿瘤大小、甲胎蛋白水平是影响胃癌患者生存预后的影响因素(P<0.05)。结论阿帕替尼联合SOX方案可延长晚期胃癌患者的生存期,且无严重不良反应发生,采用此方案治疗时可根据患者不同ECOG体力状况评分、化疗周期、TNM分期、肿瘤大小、甲胎蛋白水平评估晚期胃癌患者预后情况。Objective To explore the efficacy adverse reactions and the effective factors of prognos of apatinib combined with SOX in the treatment of advanced gastric cancer patients.Methods A total of 100 patients with advanced gastric cancer admitted to Qinhuangdao First Hospital from January 2022 to January 2023 were prospectively selected as subjects.They were divided into the control group(n=50)and the observation group(n=50)according to the random number table method.The control group received SOX regimen,and the observation group received apatinib therapy on the basis of the control group.Three weeks was a treatment cycle,and both groups were treated for 2 cycles.The efficacy,occurrence of adverse reactions,survival were compared between the two groups.The basic data of the patients were collected,including age,gender,Eastern Cooperative Oncology Group(ECOG)performance status score,pathological type,chemotherapy cycle,TNM stage,tumor size,metastasis and alpha-fetoprotein level.The influencing factors of survival and prognosis of patients in the observation group were analyzed.Results The total effective rate of treatment in the observation group was 48.00%,which was significantly higher than that in the control group(20.00%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of total adverse reactions between the observation group and the control group(P>0.05).The mean and median of overall survival time in the observation group were(10.13±0.63)and(12.03±4.07)months,respectively,which were higher than those in the control group[(7.15±0.50)and(8.01±0.41)months],the mean and median of progression-free survival time in the observation group were(10.89±0.45)and(12.12±0.31)months,respectively,which were higher than those in the control group[(8.23±0.42)and(8.45±0.46)months],the differences were statistically significant(P<0.05).Different ECOG performance status score,chemotherapy cycle,TNM stage,tumor size and AFP level were related to the su

关 键 词：胃肿瘤 预后 阿帕替尼 SOX方案 疗效 不良反应 影响因素 

分 类 号：R735.2[医药卫生—肿瘤]